Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab von Ather, Ferdows, Hamidi, Habib, Fejzo, Marlena S, Letrent, Stephen, Finn, Richard S, Kabbinavar, Fairooz, Head, Christian, Wong, Steven G

Volltext